Lathrop Investment Management Co. Buys 26,966 Shares of CVS Health Corporation $CVS

Lathrop Investment Management Co. increased its stake in CVS Health Corporation (NYSE:CVS) by 31.9% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 111,570 shares of the pharmacy operator’s stock after purchasing an additional 26,966 shares during the quarter. CVS Health makes up approximately 1.6% of Lathrop Investment Management Co.’s investment portfolio, making the stock its 28th largest position. Lathrop Investment Management Co.’s holdings in CVS Health were worth $8,411,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CVS. Harbor Capital Advisors Inc. grew its position in shares of CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 142 shares during the period. Corundum Trust Company INC acquired a new position in CVS Health during the third quarter worth approximately $29,000. Front Row Advisors LLC raised its stake in CVS Health by 436.5% in the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after buying an additional 371 shares during the period. Twin Peaks Wealth Advisors LLC bought a new position in shares of CVS Health during the 2nd quarter worth approximately $36,000. Finally, SOA Wealth Advisors LLC. raised its stake in CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after acquiring an additional 131 shares during the period. 80.66% of the stock is owned by institutional investors.

CVS Health Trading Up 2.2%

Shares of NYSE:CVS opened at $79.74 on Monday. The stock has a 50 day moving average of $78.39 and a 200 day moving average of $77.29. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The company has a market cap of $101.44 billion, a PE ratio of 57.78, a price-to-earnings-growth ratio of 0.83 and a beta of 0.49. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same period last year, the company earned $1.19 EPS. CVS Health’s quarterly revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were paid a $0.665 dividend. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. CVS Health’s dividend payout ratio (DPR) is 192.75%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on CVS shares. The Goldman Sachs Group lifted their price target on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. JPMorgan Chase & Co. lifted their price target on CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Sanford C. Bernstein reissued a “market perform” rating and set a $91.00 target price on shares of CVS Health in a research report on Tuesday, January 6th. Barclays boosted their target price on CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, TD Cowen boosted their price objective on shares of CVS Health from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Nineteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.91.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.